Galectin Therapeutics (GALT) Consolidated Net Income (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Consolidated Net Income of -$6.0 million for Q1 2026, up 37.24% year-over-year from -$4.4 million in Q1 2025, and up 43.17% quarter-over-quarter from -$10.6 million in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Consolidated Net Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$6.0 million for Q1 2026.
- In Q1 2026, Consolidated Net Income rose 37.24% year-over-year to -$6.0 million; the TTM figure through Mar 2026 stood at -$29.0 million (up 42.42% YoY), while the FY2025 annual figure was -$115.6 million, up 12.69% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$6.0 million, up from -$10.6 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$6.0 million in Q3 2025, with the low at -$17.9 million in Q4 2024.
- The 5-year median for Consolidated Net Income is -$9.9 million (2023), against an average of -$10.0 million.
- The sharpest annual moves came in 2024 and 2025: Consolidated Net Income plunged 87.42% in 2024, then surged 48.52% in 2025.
- Galectin Therapeutics' Consolidated Net Income stood at -$11.5 million in 2022, then rose by 16.92% to -$9.5 million in 2023, then slumped by 87.42% to -$17.9 million in 2024, then soared by 40.68% to -$10.6 million in 2025, then soared by 43.17% to -$6.0 million in 2026.
- Business Quant data shows GALT's Consolidated Net Income at -$6.0 million in Q1 2026, -$10.6 million in Q4 2025, and -$6.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Galectin Therapeutics | 303.68 Mn | 303.68 Mn | - | -5.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.96 Mn |
| Mar 31, 2026 | -6.03 Mn |
| Dec 31, 2025 | -5.28 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -6.43 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -14.07 Mn |
| Sep 30, 2024 | -10.47 Mn |
| Jun 30, 2024 | -12.48 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -10.33 Mn |
| Sep 30, 2023 | -9.94 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -10.76 Mn |
| Dec 31, 2022 | -10.91 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -9.90 Mn |
| Mar 31, 2022 | -10.16 Mn |
| Dec 31, 2021 | -7.70 Mn |
| Sep 30, 2021 | -8.35 Mn |